Abstract:Background Tumor immune evasion is an important hallmark of cancer. The roles of long non-coding RNAs (lncRNAs) in the process of cancer immunosurveillance remain largely unknown. In this study, we aimed to identify oncogenic lncRNAs that are involved in the immunosuppression of esophageal squamous cell carcinoma (ESCC) and investigate underlying mechanisms. Methods High-throughput sequencing and bioinformatics analysis were used to identify lncRNAs that are highly expressed in ESCC tissues and blood. Using the data from a cohort of patients in the clinical trial JSOO1, the relationship between lncRNA expression level and PD-1 mAb response (ORR and DCR) was analyzed. RNA interference and CRISPR-Cas9 were used to explore the functional roles of the lncRNA. In vivo, the human PBMC engrafted humanized xenograft model was established to assess the therapeutic responses of that specific lncRNA inhibitor and its combination with PD-1 mAb. Results Increased expression of LRTIS was observed in ESCC and was correlated with poor prognosis. Conversely, LRTIS high expression group responded better to immunotherapy (ORR 19.56% vs 9.09%, DCR 54.35% vs 18.18%). In vivo, LRTIS knockout significantly inhibited tumor growth in Hu-PBMC mice, and increased sensitivity to PD-1 mAb treatment, as shown by an increased proportion of IFN-γ+CD8+ T cells in xenografts. LRTIS could inhibit the expression of immuno-checkpoints such as PD-L1, PD-L2 and IDO1. Mechanistically, LRTIS was directly associated with MLL1 and significantly affected MLL1 stability by inhibiting its ubiquitination and subsequent proteasomal degradation. LRTIS competitively bonded to MLL1 preventing ASB2 from binding to MLL1, which explained MLL1 ubiquitination inhibition. Knocking out LRTIS, resulted in MLL1 mediated H3K4me decrease in the promoter region of immuno-checkpoints, causing their downregulation. Clinically, dysregulation of LRTIS-MLL1-PD-L1 axis could also be observed in patients. Conclusions The LRTIS plays an essential role in ESCC immunosuppression by binding to and stabilizing MLL1. This study identified a novel immuno-checkpoint regulating lncRNA and revealed a novel mechanism underlying lncRNA-mediated cancer immuno-microenvironment remodeling. Translational studies further implicated that LRTIS is a promising prognostic biomarker for cancer immunotherapy, and a potential target for immunotherapy.

LncRNA HHIP-AS1 suppresses lung squamous cell carcinoma by stabilizing HHIP mRNA

Natural Antisense Long Noncoding RNA HHIP-AS1 Suppresses Non-Small-Cell Lung Cancer Progression by Increasing HHIP Stability via Interaction with CELF2

Long Non‑coding RNA HHIP‑AS1 Inhibits Lung Cancer Epithelial‑mesenchymal Transition and Stemness by Regulating PCDHGA9.

LINC01207 Promotes the Progression of Non-Small Cell Lung Cancer Via Regulating ARHGAP11A by Sponging Mir-525-5p

LINC00511 Promotes Lung Squamous Cell Carcinoma Proliferation and Migration Via Inhibiting Mir-150-5p and Activating TADA1

lncRNA HHIP-AS1/HHIP modulates osteogenic differentiation of BM-MSCs by regulating Hedgehog signaling pathway

IDDF2020-ABS-0118 Long Non-Coding RNA LRTIS Regulates MLL1-mediated Immunocheckpoint Remodelling in Esophageal Squamous Cell Carcinoma

LINC01018 Confers a Novel Tumor Suppressor Role in Hepatocellular Carcinoma Through Sponging Microrna-182-5p

Knockdown of lncRNA LEF1-AS1 inhibited the progression of oral squamous cell carcinoma (OSCC) via Hippo signaling pathway

LncRNA HULC Promotes Non-Small Cell Lung Cancer Cell Proliferation and Inhibits the Apoptosis by Up-Regulating Sphingosine Kinase 1 (SPHK1) and Its Downstream PI3K/Akt Pathway

Upregulation of HOXA1 Promotes Tumorigenesis and Development of Non‑small Cell Lung Cancer: A Comprehensive Investigation Based on Reverse Transcription-Quantitative Polymerase Chain Reaction and Bioinformatics Analysis.

Inhibition of HHIP Promoter Methylation Suppresses Human Gastric Cancer Cell Proliferation and Migration

Hypermethylated in cancer 1(HIC1) suppresses non-small cell lung cancer progression by targeting interleukin-6/Stat3 pathway.

LncRNA RUNX1-IT1 Which is Downregulated by Hypoxia-Driven Histone Deacetylase 3 Represses Proliferation and Cancer Stem-Like Properties in Hepatocellular Carcinoma Cells

The HHIP-AS1 lncRNA promotes tumorigenicity through stabilization of dynein complex 1 in human SHH-driven tumors

USF1-induced upregulation of LINC01048 promotes cell proliferation and apoptosis in cutaneous squamous cell carcinoma by binding to TAF15 to transcriptionally activate YAP1

HHIP Gene Overexpression Inhibits the Growth, Migration and Invasion of Human Liver Cancer Cells.

Downregulation of Long Noncoding RNA in Non-Homologous End Joining Pathway 1 Inhibits the Progression of Esophageal Squamous Cell Carcinoma

Hypoxia-Regulated Lncrna USP2-AS1 Drives Head and Neck Squamous Cell Carcinoma Progression.

Long non-coding RNA CCDC183-AS1 acts AS a miR-589-5p sponge to promote the progression of hepatocellular carcinoma through regulating SKP1 expression

Silencing of Long Noncoding RNA HOXD-AS1 Inhibits Proliferation, Cell Cycle Progression, Migration and Invasion of Hepatocellular Carcinoma Cells Through MEK/ERK Pathway.